Medical Doctor Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

Rajeev Saggar

Pulmonary Disease Phoenix, AZ Medical Doctor

NPI 1225230543 CMS profile 146204

500 W Thomas Rd, Suite 500, Phoenix, AZ 85013

Open in the dashboard

General payments

$161,139

257 records reported · program years 2019–2024

Research payments

$0

Paid to them · None reported · program years 2019–2024

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$57,442 paid to institutions, not to them · program years 2019–2020

Through program year 2024, Rajeev Saggar of Phoenix, AZ is reported in the CMS Open Payments database as having received $161,139 across 257 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $57,442 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 97th percentile of Pulmonary Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $33 1
2023 General $24 1
2022 General $3,150 1
2020 General $12,301 14
2019 General $145,631 240

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Rajeev Saggar
  • Pulmonary Disease median
  • Middle half of Pulmonary Disease
  • National median

In program year 2025, general payments to Rajeev Saggar were reported at $0. Among 8,914 Pulmonary Disease profiles paid that year, the median was $500 and the middle half received between $124 and $1,893.

Show as a table
Year Rajeev Saggar Pulmonary Disease median Middle half National median
2019 $145,631 $377 $109–$1,340 $163
2020 $12,301 $230 $56–$907 $114
2021 $0 $269 $68–$1,072 $132
2022 $3,150 $390 $100–$1,457 $149
2023 $24 $419 $114–$1,659 $160
2024 $33 $476 $123–$1,818 $164
2025 $0 $500 $124–$1,893 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. Boehringer Ingelheim Pharmaceuticals, Inc. $51,945 37 payments
  2. United Therapeutics Corporation $31,192 45 payments
  3. Bayer HealthCare Pharmaceuticals Inc. $29,395 41 payments
  4. Genentech USA, Inc. $24,643 29 payments
  5. Actelion Pharmaceuticals US, Inc. $20,257 27 payments
  6. Neuronetics, Inc. $1,250 6 payments
  7. Pulmonx Corporation $706 7 payments
  8. Janssen Research & Development, LLC $339 3 payments
  9. Grifols USA, LLC $279 11 payments
  10. Sandoz Inc. $258 7 payments
  11. Other $876 44 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $78,493 24 payments
  2. Consulting Fee $51,970 8 payments
  3. Travel and Lodging $23,556 63 payments
  4. Food and Beverage $7,109 161 payments
  5. Education $13 1 payment
Products named General payments · program years 2019–2024
  1. OFEV $47,013 32 payments
  2. Adempas $29,395 41 payments
  3. Esbriet $24,544 24 payments
  4. NONE $14,400 1 payment
  5. ORENITRAM $8,750 26 payments
  6. TYVASO $8,484 25 payments
  7. UPTRAVI $6,541 9 payments
  8. NEUROSTAR TMS THERAPY $1,250 6 payments
  9. Pulmonx Endobronchial Valve EBV $706 7 payments
  10. REMODULIN $609 10 payments
  11. Other $2,210 84 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

257 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pulmonary Disease in Arizona

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record